Day 3 Program

Educational Session 12: New Frontiers in Breast Cancer—Targeting Therapy Resistance

Day 3: December 11, 2025

2:30 PM–4:15 PM CST

Hemisfair 1-2

Session Details

The session explored mechanisms and potential strategies to overcome resistance in endocrine therapy, CDK4/6 inhibitors, and antibody-drug conjugates in breast cancer.

ED12-02

Insights in CDK4/6 inhibitor resistance in breast cancer

Seth A Wander, Mass General Cancer Center, Boston, MA

ED12-03

ADC resistance in breast cancer

Leif W. Ellisen, Massachusetts General Hospital Cancer Center, Boston, MA

Advocate

Michelle Audoin, Canadian Institutes of Health Research (CIHR), Toronto, ON, Canada